System Modeling of a large FPGA project: the SKA Tile Processing Module

Large projects like the SKA have an intrinsic complexity due to their scale. In this context, the application of a management design system becomes fundamental. For this purpose the SysML language, a UML customization for engineering applications, has been applied. As far as our work is concerned, we focused on the SKA Low Telescope - Tile Processing Module, designing diagrams at different detail levels. We designed a conceptual model of the TPM, primarily focusing on the main interfaces and the major data flows between product items. Functionalities are derived from use cases and allocated to hardware modules in order to guarantee the project's internal consistency and features. This model has been used both as internal documentation and as job specification, to commit part of the design to external entities

Radioastronomic signal processing cores for the SKA radio telescope

Modern radio telescopes require the processing of wideband signals, with sample rates from tens of MHz to tens of GHz, and are composed from hundreds up to a million of individual antennas. Digital signal processing of these signals include digital receivers (the digital equivalent of the heterodyne receiver), beamformers, channelizers, spectrometers. FPGAs present the advantage of providing a relatively low power consumption, relative to GPUs or dedicated computers, a wide signal data path, and high interconnectivity. Efficient algorithms have been developed for these applications. Here we will review some of the signal processing cores developed for the SKA telescope. The LFAA beamformer/channelizer architecture is based on an oversampling channelizer, where the channelizer output sampling rate and channel spacing can be set independently. This is useful where an overlap between adjacent channels is required to provide an uniform spectral coverage. The architecture allows for an efficient and distributed channelization scheme, with a final resolution corresponding to a million of spectral channels, minimum leakage and high out-of-band rejection. An optimized filter design procedure is used to provide an equiripple response with a very large number of spectral channels. A wideband digital receiver has been designed in order to select the processed bandwidth of the SKA Mid receiver. The receiver extracts a 2.5 MHz bandwidth form a 14 GHz input bandwidth. The design allows for non-integer ratios between the input and output sampling rates, with a resource usage comparable to that of a conventional decimating digital receiver. Finally, some considerations on quantization of radioastronomic signals are presented. Due to the stochastic nature of the signal, quantization using few data bits is possible. Good accuracies and dynamic range are possible even with 2-3 bits, but the nonlinearity in the correlation process must be corrected in post-processing. With at least 6 bits it is possible to have a very linear response of the instrument, with nonlinear terms below 80 dB, providing the signal amplitude is kept within bounds

The Gender-Climate-Security Nexus: Conceptual Framework, CGIAR Portfolio Review, and Recommendations towards an Agenda for One CGIAR

This position paper provides a conceptual framework for the gender-climate-security-nexus, a CGIAR portfolio review of work related to the nexus, and recommendations towards an agenda for One CGIAR in addressing the nexus. We anticipate the paper will help inform the One CGIAR and its stakeholders towards an understanding of the connections between gender, climate, and security through case study examples of the gender dimensions of climate-related security risks, a review of the CGIAR work to date on the gender-climate-security nexus and how this work can be used to promote gender transformative goals in climate security research, policy, and programming, as well as recommendations for One CGIAR on what actions should be taken to inform future research and policy in addressing gendered climate impacts and associated threats to human security

INVESTIMENTO EM SUSTENTABILIDADE E O IMPACTO MERCADOLÓGICO: UMA AVALIAÇÃO A PARTIR DO SCORE ESG

Sustainability draws attention because it allows the creation of value for various stakeholders in the business environment and becomes part of the marketing concerns of corporations of the most varied segments and sizes. This article aims to evaluate the impact of investments in sustainability activities (environmental, social and economic) on the marketing performance of companies. Therefore, a descriptive quantitative research was developed with 1,231 companies that appear in the Asset4 Refinitiv database (Thomson Reuters) that have classifications in the ESG Score - Environmental, Social and Governance, using the panel data technique with multilevel hierarchical model. Based on the models generated with the dependent variables: return on sales, return on investment in marketing, sales and marketing and advertising expenses, it was found in this study that specific and targeted actions promote more market results than combined actions, highlighting the social score. The findings contribution allows us to understand the nuances of the dimensions of sustainability from a marketing perspective, with implications for investors, companies and researchers.  A sustentabilidade chama atenção por possibilitar a criação de valor para vários stakeholders no âmbito empresarial e torna-se parte das preocupações mercadológicas de corporações dos mais variados segmentos e tamanhos. O presente artigo tem como objetivo avaliar o impacto de investimentos em atividades de sustentabilidade (ambientais, sociais e econômicas) no desempenho mercadológico das empresas. Para tanto, desenvolveu-se uma pesquisa quantitativa descritiva com 1.231 empresas presentes no banco de dados Asset4 do Refinitiv (Thomson Reuters) que possuem classificações no índice ESG - Environmental, Social and Governance, utilizando-se da técnica de dados em painel com modelo hierárquico multinível. A partir dos modelos gerados com as variáveis dependentes: retorno sobre as vendas, retorno sobre o investimento em marketing, vendas e marketing e despesas com publicidade, encontrou-se neste estudo que ações específicas e direcionadas promovem mais resultados mercadológicos do que ações combinadas, destacando-se os efeitos no pilar social. A contribuição dos achados permite compreender as nuances das dimensões da sustentabilidade sob o olhar mercadológico, com implicações aos investidores, empresas e pesquisadores

Estudios citogenéticos y mecanismos moleculares en los Síndromes Mielodisplásicos

Las alteraciones genéticas debidas a mutaciones, hallazgos cromosómicos balanceados o no, disomía uniparental adquirida, haploinsuficiencia y los fenómenos epigenéticos estarían involucrados al inicio y en la progresión de los SMD. Entre los genes implicados se encuentran el NRAS, FLT3, TP53, RUNX1, p15INK4b, TET2, ASXL1 y RPS14. Un 30-59% de pacientes con SMD de novo presentan cariotipos alterados y este porcentaje se incrementa según el riego de los subtipos FAB o WHO. Las aberraciones citogenéticas más frecuentes son: -5/del(5q) [2%-11%], -7/del (7q) [2%-5%], +8 [3%-12%], del(20q) [2%-4%], –Y [2%-4%] y cariotipos complejos (≥3 alteraciones) [10-20%]. Un 60-90% de los SMD secundarios presentan cariotipos anormales, un aumento de translocaciones y de cariotipos complejos [50%]. Las alteraciones en los cromosomas 5/7 [80%] se asocian con exposición a agentes alquilantes y los rearreglos 11q23 o 21q22 con exposición a inhibidores de topoisomerasa II. El cariotipo ayuda en el diagnóstico, pronóstico, tratamiento y seguimiento de los pacientes. La categorización del riesgo citogenético del IPSS ha sido comprobada aplicando las clasificaciones FAB y WHO, y validada en el WPSS. Aunque el grupo Intermedio es heterogéneo, el Consenso Internacional en Citogenética de los SMD sugiere la continuidad de su utilización hasta que se realice un nuevo estudio multicéntrico.Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética; ArgentinaFil: Benasayag, Silvia. Fundagen; ArgentinaFil: Gallino, María Inés. Fundagen; ArgentinaFil: Correa, Walter A. Fundagen; ArgentinaFil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex". Departamento de Genética; Argentin

Contribution of polymorphisms in IFNG and TNF to complications of the allogeneic hematopoietic stem cell transplantation with sibling donors

Las complicaciones del trasplante alogénico de células progenitoras hematopoyéticas (TACPH) relacionado incluyen tiempos variables de engraftment,enfermedad injerto contra huésped (EICH), infeccionesbacterianas y reactivación de citomegalovirus(CMV), entre otras. La existencia de polimorfismosen genes no HLA que codifican citoquinas proinflamatoriastales como el factor de necrosis tumoralalfa (TNF) e interferón gamma (IFNG) condicionaría la aparición de estas complicaciones. Se evaluóel impacto de la variante +1349 CAn del gen INFG y del polimorfismo -308 G/A de TNF en el engraftment y en la EICH en 148 receptores de TACPHrealizados en los centros participantes. Con respecto al engraftment tardío (≥15 días), el análisis multivariado confirmó el poder predictivo desfavorable del genotipo CAno12/no12 (baja producción) de IFNG(OR 3,9; p=0,003), médula ósea (MO) como fuente de células progenitoras (OR 4,6; p=0,013) y bacteriemia (OR 3,0; p=0,033). En relación a EICHa 3-4,las variables independientes fueron el genotipo de baja producción de IFNG (OR 0,1; p=0,008), bacteriemia (OR 3,3; p=0,048) y presencia de CMV(OR3,3; p=0,046). Y con respecto a EICHc, el riesgo fue influenciado por el genotipo -308 GG (producción baja) de TNF (OR 3,3; p=0,038), SP como fuente (OR 5,0; p=0,028), acondicionamiento mieloablativo (OR 3,3; p=0,014) y antecedente de EICHa 2-4 (OR 2,6; p=0,029). Aunque es necesario confirmar estos hallazgos, el genotipo de baja producción de IFNG se asoció con engraftment tardío y menor EICHa, mientras que los genotipos de baja producción de TNF se relacionaron con mayor incidencia de EICHc. Las variantes polimórficas estudiadas contribuirían al desarrollo de complicaciones en pacientes con TACPH relacionado.Complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) include variable engraftment times, acute (aGVHD) and chronic (cGVHD) graft-versus-host diseases, bacterial infections and reactivation of cytomegalovirus (CMV), among others. The existence of polymorphisms in non-HLA genes that encode pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF) and interferon gamma (IFNG) would condition the appearance of these complications. The impact of polymorphic variants +1349 CAn of INFG gene and -308 G/A of TNF was evaluated on the engraftment and GVHD in 148 allo-HSCT recipients with sibling donors. In the multivariate analysis, the genotype CAno12/no12 (low production) of INFG (OR 3.9, p=0.003), bone marrow (BM) as source of progenitor cells (OR 4.6, p=0.013) and bacteremia (OR 3.0, p=0.033) maintained their predictive power with respect to late engraftment (≥15 days). Genotype of low IFNG production (OR 0.1, p=0.008), bacteremia (OR 3.3, p=0.048) and presence of CMV (OR 3.3, p=0.046) showed a significant association with aGVHD 3-4. And with respect to cGVHD, the genotype -308 GG (low production) of TNF (OR 3.3, p=0.038), PB as source (OR 5.0, p=0.028), myeloablative conditioning (OR 3.3, p=0.014) and previous aGVHD 2-4 (OR 2.6, p=0.029). Although it is necessary to confirm these findings, the genotype of lower IFNG production was associated with a later engraftment and less severe aGVHD and genotypes of lower TNF production was related to a higher incidence of cGVHD contributing to the development of complications in allo-HSCT.Fil: Palau Nagore, Maria Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Berro, Mariano. Universidad Austral; ArgentinaFil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Rivas, M.M.. Universidad Austral; ArgentinaFil: Foncuberta, C.. Instituto Alexander Fleming; ArgentinaFil: Vitriu, A.. Instituto Alexander Fleming; ArgentinaFil: Remaggi, G.. Fundaleu; ArgentinaFil: Martínez Rolón, J.. Fundaleu; ArgentinaFil: Jaimovich, Sebastian Gaston. Fundación Favaloro; ArgentinaFil: Requejo, A.. Fundación Favaloro; ArgentinaFil: Padros, K.. Primer Centro Argentino de Inmunogenética; ArgentinaFil: Rodríguez, M.B.. Primer Centro Argentino de Inmunogenética; ArgentinaFil: Kusminsky, G.. Universidad Austral; ArgentinaFil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentin

Myelodysplastic syndromes in Latin America: State of the art

Latin America is a group of countries that covers an area of approximately 19 197 000 km2. In 2016, itspopulation was estimated at more than 639 million. The prevalent languages are Spanish andPortuguese.Myelodysplastic syndromes (MDSs) are a heterogeneous group of myeloid neoplasms characterized byabnormal differentiation and maturation of myeloid cells, bone marrow failure, and genetic instability withenhanced risk of transforming to acute myeloid leukemia.The incidence rates for MDS in Europe and the United States range from 3 to 5 per 100 000 personyearsand increase markedly with age to 20 per 100 000 person-years for those older than age 70 years.Despite the absence of epidemiologic data, Latin America also has an aging population, as with otherdeveloped countries, and an increasing rate of secondary MDS from previous toxic exposure not only asa consequence of treating other malignancies but also as a result of environmental or occupationalfactors. Diagnosis and treatment remain difficult because of the high number of economic andtechnological disparities within and among Latin American countries.Fil: Crisp, Renée. Hospital Nacional "a Posadas"; ArgentinaFil: Grillé, Sofía. Hospital de Clínicas; UruguayFil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Diaz, Lilian. Hospital de Clínicas; UruguayFil: Undurraga, Soledad. Hospital El Salvador; ChileFil: Navarro, Juan. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Vidal, Gabriela. Hospital Nacional Edgardo Rebagliati Martins; PerúFil: Gusmao, Breno. Hospital Israelita Albert Einstein; BrasilFil: Reyes, Jheremy. Clínica Los Nogales; ColombiaFil: Huaman Garaicoa, Fuad. Instituto Oncológico Nacional Dr. J. Tanca Marengo; EcuadorFil: Magalhaes, Silvia. Universidade Federal Do Ceara; BrasilFil: Barroso, Fernando. Universidade Estadual do Ceará; BrasilFil: Ovilla, Roberto. Hospital Angeles Lomas; MéxicoFil: Flores, Gabriela. Gobierno de Ciudad de Buenos Aires. Hospital General de Agudos "Carlos G. Durand"; ArgentinaFil: Choque, Juan. Hospital de Especialidades Materno Infantil; BoliviaFil: Distéfano, Marcos. Hospital Domingo Luciani; VenezuelaFil: Salinas Viedma, Victor. Instituto de Prevision Social; ParaguayFil: Iastrebner, Marcelo. Sanatorio Sagrado Corazón; Argentin

Application of the revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes (MDS) in 511 Argentinean patients

El Índice Pronóstico Internacional, el “gold standard” de los sistemas disponibles para predecir el comportamiento de los pacientes con SMD, ha sido recientemente revisado (IPSS-R). Nuestro objetivo fue aplicar el IPSS-R en pacientes de población Argentina debido a su factible utilización en la práctica diaria. Se analizó una serie de 511 pacientes (290 pertenecientes al Registro Argentino de Enfermedades Hematológicas) con SMD de novo (1981-2013), con una edad mediana de 70 años y una relación de sexos M/F de 1,3. Durante el seguimiento (mediana de sobrevida: 44 meses), 22% de los pacientes presentaron progresión leucémica y 43% fallecieron. La descripción demográfica, la distribución de los parámetros clínicos, citogenéticos y grupos de riesgo según el IPSS, y los respectivos tiempos de sobrevida y de progresión leucémica, obtenidos en nuestra serie fueron similares a los descriptos en el trabajo original. Los pacientes fueron clasificados según el IPSS-R en: 104 (20%) Muy Bajo, 209 (41%) Bajo, 75 (15%) Intermedio, 71 (14%) Alto y 52 (10%) Muy Alto, con una sobrevida (50%) de 125, 62, 34, 19 y 13 meses (p<0,001) y tiempo de progresión leucémica (25%) de 125, 124, 23, 6 y 5 meses (p<0,001), respectivamente. Los pacientes categorizados según el IPSS fueron re-distribuidos en las categorías definidas por el IPSS-R (Kendall’s tau= 0,702) mostrando que el grupo de riesgo Intermedio-1 representa el 83% (62/75) del riesgo Intermedio y el 24% (17/71) del riesgo Alto. La edad y el sexo mostraron diferencias significativas para predecir sobrevida en los grupos de menor riesgo. La aplicación del IPSS-R ajustado por edad permitió individualizar un 18% de pacientes de riesgo Bajo con una sobrevida significativamente menor (23 meses, p<0,001). El IPSS-R resultó simple de aplicar debido a que incluye variables accesibles mostrando una buena reproducibilidad en la diferenciación de grupos de riesgo en nuestra población.The International Prognostic Scoring System, the gold standard for risk assessment in MDS, has been recently revised (IPSS-R). The aim of this study was to apply the IPSS-R in Argentinean MDS patients. We retrospectively analyzed a cohort of 511 (290 patients belong to the MDS Registry promoted by the SAH) de novo MDS patients (1981-2013). The median age was 70 (17-92) with a gender ratio of 1.3. During the follow-up (median overall survival: 44 months), 22% evolved to AML and 43% died. The demographic description, obtained percentages, survival times and time to leukemic evolution for our patients regarding cytogenetic, hematological parameters, and IPSS subgroups were similar to the IWG-PM database. Patients were classified by IPSS-R as very-low (20%), low (41%), intermediate (15%), high (14%), and very-high risk (10%), with median survival of 125, 62, 34,19 and 13 months (p<0.001), and time to leukemic evolution (25%) of 125, 124, 23, 6, and 5 months, respectively (p<0.001). The IPSS-R showed effective separation of the IPSS risk categories (Kendall’s tau= 0.702) and the intermediate group was mainly (83%) composed by intermediate-1 IPSS risk patients. Age and gender sowed statistical differences for predicting survival in the very low/ low risk group (p=0.001). The proposed age-adjusted categorization helped us to identify 18% among low risk IPSS-R patients with an inferior median survival (23 months, p<0,001). It can be concluded that the IPSS-R system was simple to use since includes accessible variables showing a good reproducibility and effectiveness in predicting clinical outcome in our series.Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Prates, M. V.. Hospital Italiano; ArgentinaFil: Sakamoto, F.. Grupo Montecaseros; ArgentinaFil: Alfonso, Guillermo. Provincia de Buenos Aires. Ministerio de Salud. Hospital Nacional “Profesor Alejandro Posadas”; ArgentinaFil: Rosenhain, M.. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Dr. Enrique Tornú"; ArgentinaFil: Narbaitz, M.. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex"; ArgentinaFil: Gonzalez, J.. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Carlos G. Durand"; ArgentinaFil: Bengió, R.. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex"; ArgentinaFil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina. Academia Nacional de Medicina de Buenos Aires. Instituto de Investigaciones Hematológicas "Mariano R. Castex"; Argentin

Prognostic impact of bone marrow fibrosis in primary myelodysplastic syndromes

La mielofibrosis (MF) se observa en el 10-20% de los pacientes con síndrome mielodisplásico (SMD). Su presencia es reconocida como un hallazgo histológico adverso asociado a curso agresivo, fallo medular temprano, sobrevida acortada y evolución leucémica.El objetivo fue examinar la influencia de la MF (MF ≥1) en la sobrevida global (SG) y su asociacióncon variables clínicas e histopatológicas.Se identificaron 468 pacientes con SMD incluidos en el Registro Argentino de SMD de 2007 a 2017.La mediana de SG del subgrupo MF ≥1 fue de 20,1 meses (IC 95%: 10,1-30,0) versus 67,6 meses (IC95% 45,1-90,3) del subgrupo MF-0 (p2 (HR 2,07, 95% IC 1,44-2,96; p5% (HR 2,94,IC 95% 2,06-4,20; p3 (HR 2,17; IC 95%: 1,48-3,19;p1000 ug/L (OR 3,41; p= 0,006) y la localización eritroide atípica (OR 2,65; p=0,004) se asociaron significativamente con la presencia de MF ≥1.Los resultados destacan la presencia de MF ≥1 como un factor pronóstico adverso para la supervivencia en SMD, asociado con hiperferritinemia y alteración de la localización de la progenie eritroide en la MO.Myelofibrosis (MF) is observed in 10-20% of patients with myelodysplastic syndrome (MDS). The presence of MF has been recognized as an adverse histological finding associated with an aggressive course including early bone marrow (BM) failure, shortened survival and leukemic evolution. The aim of this study was to examine the influence of the myelofibrosis (MF ≥1) in the overall survival (OS) and its association with clinical and histopathologic variables. We identified 468 MDS patients who were included in the Argentinian Registry of MDS from 2007 to 2017. The median OS for the MF≥1 subgroup was 20.1 months (95% CI 10.1-30.0) versus 67.6 months (95% CI 45.1-90.3) for the MF-0 subgroup (p2 (HR 2.07, 95% CI 1.44-2.96; p5% (HR 2.94, 95% CI 2.06-4.20; p3 (HR 2.17, 95% CI 1.48- 3.19; p 1000 ug/L (OR 3.41; p=0.006) and the atypical erythroid localization (OR 2.65; p=0.004) were significantly associated with the presence of MF ≥1. Our results highlight the presence of any grade of myelofibrosis as an independent adverse prognostic factor for survival in MDS, associated with higher ferritin level and abnormal erythroid localization in the BM.Fil: Russo, Maria Florencia. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal General de Agudos Paroissien (higa Paroissien); ArgentinaFil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Enrico, Alicia. Hospital Italiano de La Plata; ArgentinaFil: Arbelbide, Jorge. Hospital Italiano; ArgentinaFil: Narbaitz, Marina. Academia Nacional de Medicina de Buenos Aires; ArgentinaFil: de Dios Soler, Marcela. Hospital Municipal de Oncologia Maria Curie ; Gobierno de la Ciudad Autonoma de Buenos Aires;Fil: Garcia Rivello, Hernan Jorge. Hospital Italiano; ArgentinaFil: Martin, Carlos. Hospital Italiano de La Plata; ArgentinaFil: Iastrebner, Marcelo. Sanatorio Sagrado Corazón; ArgentinaFil: Gonzalez, Jacqueline. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; ArgentinaFil: Rosenhain, Mariana. Hospital General de Agudos Dr. Enrique Tornú; ArgentinaFil: Alfonso, Graciela. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Kornblihtt, Laura Inés. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaFil: Perusini, Agustina. Hospital Italiano; ArgentinaFil: Lazzarino, Carolina. Gobierno de la Provincia de Buenos Aires. Hospital Interzonal General de Agudos Paroissien (higa Paroissien); Argentin